Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556345 | 0.90 | RXFP1 (0.43) | RXFP1ABCG2MTORTRPV4MAPK8 | |
| SCHEMBL22556350 | 0.90 | TRPV4 (0.43) | RXFP1ABCG2MTORTRPV4MAPK8 | |
| SCHEMBL22571429 | 0.89 | RXFP1 (0.46) | RXFP1ABCG2MAPK8TAS2R14 | |
| SCHEMBL30463789 | 0.89 | RXFP1 (0.46) | RXFP1ABCG2MAPK8TAS2R14 | |
| SCHEMBL30463790 | 0.88 | PSMB5 (0.43) | RXFP1ABCG2MAPK8TAS2R14AKR1C3 | |
| SCHEMBL22571359 | 0.88 | PSMB5 (0.43) | RXFP1ABCG2MAPK8TAS2R14AKR1C3 | |
| SCHEMBL23701543 | 0.87 | RXFP1 (0.48) | RXFP1ABCG2MTORMAPK8TAS2R14 | |
| SCHEMBL23713162 | 0.87 | RXFP1 (0.43) | RXFP1ABCG2MTORTRPV4MAPK8 | |
| SCHEMBL22556464 | 0.87 | RXFP1 (0.43) | RXFP1ABCG2MAPK8TAS2R14AKR1C3 | |
| SCHEMBL30463784 | 0.87 | RXFP1 (0.43) | RXFP1ABCG2MTORTRPV4MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885ABCG2 2985/4885MTOR 219/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885ABCG2 2985/4885MTOR 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.